Tandem Diabetes Care TNDM Pump — Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tandem Diabetes Care's pump — sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tandem Diabetes Care's pump — sales?
- Tandem Diabetes Care (TNDM) reported pump — sales of $110.4M in Q1 2026.
- How has Tandem Diabetes Care's pump — sales changed year-over-year?
- Tandem Diabetes Care's pump — sales increased by 8.1% year-over-year, from $102.1M to $110.4M.
- What is the long-term trend for Tandem Diabetes Care's pump — sales?
- Over 3 years (2022 to 2025), Tandem Diabetes Care's pump — sales has grown at a 2.4% compound annual growth rate (CAGR), from $431.91M to $464.15M.
- What does pump — sales mean?
- This metric represents the total revenue generated from the sale of durable insulin delivery devices and associated hardware components. It serves as a primary indicator of market adoption for the company's core medical device technology and reflects the success of product lifecycle management. Tracking this revenue stream helps investors assess the company's competitive position within the insulin pump market and the impact of new product launches on top-line growth.